Description: Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Home Page: www.conduitpharma.com
4995 Murphy Canyon Road
San Diego,
CA
92123
United States
Phone:
760 471 8536
Officers
| Name | Title |
|---|---|
| Dr. David Joszef Tapolczay | CEO & Director |
| Mr. James Bligh | Interim CFO & Director |
| Dr. Joanne M. Holland | Chief Scientific Officer |
| Mr. Bill Begien | Senior VP of Investor Relations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-09-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |